Area of Research: Drug Resistance
2020 Grant Recipients
-
Elizabeth Lee, MD,
Dana Farber Cancer Institute
Ann and Sol Schreiber Mentored Investigator AwardPhase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
-
Sunila Pradeep, PhD,
Medical College of Wisconsin
Liz Tilberis Early Career AwardEpigenetic Causes of Acquired Resistance of Anti-VEGF Therapy
-
Janice Santiago, PhD,
MD Anderson Cancer Center
Ann and Sol Schreiber Mentored Investigator AwardCrizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
-
Morozov Yaroslav, PhD,
University of Pennsylvania
Ann and Sol Schreiber Mentored Investigator AwardThe BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
2019 Grant Recipients
-
Alexander Cole, PhD,
Magee-Womens Research Institute
Ann and Sol Schreiber Mentored Investigator AwardInvestigating Regulators of Quiescence in Epithelial Ovarian Cancer
-
Haineng Xu, PhD,
University of Pennsylvania
Ann and Sol Schreiber Mentored Investigator AwardA Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
-
Elizabeth Stover, MD, PhD,
Dana Farber Cancer Institute
Liz Tilberis Early Career AwardTargeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer
2018 Grant Recipients
-
Damayanti Chakraborty, PhD,
Massachusetts General Hospital
Ann and Sol Schreiber Mentored Investigator AwardUnderstanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
-
Goldie Lui, PhD,
Fred Hutchinson Cancer Research Center
Ann and Sol Schreiber Mentored Investigator AwardIdentifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
-
Yinu Wang, PhD,
Northwestern University
Ann and Sol Schreiber Mentored Investigator AwardCharacterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
-
Gordon Mills, MD, PhD,
MD Anderson Cancer Center
Collaborative Research Development GrantRational Combination Therapy in Ovarian Cancer
-
Jian Yuan, PhD,
Mayo Clinic
Liz Tilberis Early Career AwardThe Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer
-
David Sabatini, MD, PhD,
Whitehead Institute for Biomedical Research
Collaborative Research Development GrantA Personalized Approach to Identify and Target Ovarian Cancer Liabilities
2017 Grant Recipients
-
Ilana Chefetz, PhD,
University of Michigan
Liz Tilberis Early Career AwardDrugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian Cancer
-
Beatrice Rondinelli, PhD,
Dana Farber Cancer Institute
Ann and Sol Schreiber Mentored Investigator AwardEZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
-
Sunila Pradeep, PhD,
Medical College of Wisconsin
Liz Tilberis Early Career AwardEpigenetic Causes of Acquired Resistance to Anti-VEGF Therapy
2016 Grant Recipients
-
Jill Madden, PhD,
Inc., University of Kansas Medical Center Research Institute
Ann and Sol Schreiber Mentored Investigator AwardThe Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
-
Beth Y. Karlan, MD,
Cedars-Sinai Medical Center
Collaborative Research Development GrantCo-Evolution of Epithelial Ovarian Cancer and Tumor Stroma
-
Zihua Gong, MD, PhD,
MD Anderson Cancer Center
Liz Tilberis Early Career AwardDNA Repair Pathways as Target for Therapy-Resistant Ovarian Cancer
2014 Grant Recipients
-
Selvendiran Karuppaiyah, PhD,
Ohio State University
Liz Tilberis Early Career AwardNew Type of Experimental Drug for Ovarian Cancer
-
S John Weroha, MD, PhD,
Mayo Clinic
Liz Tilberis Early Career AwardOvarian Cancer Surrogates to Study Platinum Resistance
-
Nima Aghaeepour, PhD,
Stanford University
Ann and Sol Schreiber Mentored Investigator AwardComputationally-guided Characterization of Therapy-resistant Ovarian Tumors
-
Raphael Ceccaldi, PharmD, PhD,
Dana Farber Cancer Institute
Ann and Sol Schreiber Mentored Investigator AwardA Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
-
Kyung Hee Noh, PhD,
MD Anderson Cancer Center
Ann and Sol Schreiber Mentored Investigator AwardTargeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
-
Yang Yang, PhD,
Yale University
Ann and Sol Schreiber Mentored Investigator AwardP53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
-
Yuyu Yuyu, PhD,
Johns Hopkins University School of Medicine
Ann and Sol Schreiber Mentored Investigator AwardTargeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer
2013 Grant Recipients
-
Elizabeth Swisher, MD,
University of Washington
Collaborative Research Development GrantThe FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas
2012 Grant Recipients
-
Ivan Garcia-Bassets, PhD,
University of California - San Diego
Liz Tilberis Early Career AwardTargeting the Epigenetic Plasticity of the Platinum Response in Drug-resistant Ovarian Cancer Cells
-
W. Ruprecht Wiedemeyer, PhD,
Cedars-Sinai Medical Center
Liz Tilberis Early Career AwardOvarian Cancer Evolution After Targeted Therapy
2011 Grant Recipients
-
Kenneth Nephew, PhD,
Indiana University
Collaborative Research Development GrantA New Approach to Treating Recurrent Ovarian Cancer and Newly Diagnosed Disease
-
Weiping Zou, MD, PhD,
University of Michigan - Ann Arbor
Collaborative Research Development GrantUnderstanding how Ovarian Cancer Stem Cells Play a Role in Disease Progression and Drug Resistance
-
Analisa DiFeo, PhD,
moun, Mount Sinai School of Medicine and Case Western Reserve University
Liz Tilberis Early Career AwardWhat is the Relationship Between an miRNA Molecule and Resistance to Chemotherapy?
-
Selvendiran Karuppaiyah, PhD,
Ohio State University
Liz Tilberis Early Career AwardSafe, Targeted, Antitumor Therapeutics (STAT3 Inhibitors) for Ovarian Cancer
-
Mary Zhang, MS, PhD,
University South Florida
Liz Tilberis Early Career AwardUnderstanding Mechanisms that Lead to Resistance to Platinum-based Treatments
2009 Grant Recipients
-
Anil K. Sood, MD,
MD Anderson Cancer Center
Collaborative Research Development GrantNovel Treatments for Ovarian Cancer Using siRNAs
2008 Grant Recipients
-
Xiaoping He, MD, PhD,
Mayo Clinic Rochester
Ann and Sol Schreiber Mentored Investigator AwardUnderstanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer
2006 Grant Recipients
-
Aliza Leiser, MD,
Yale University
Ann and Sol Schreiber Mentored Investigator AwardClinical Implications of the TLR-4MYD88 Pathway in EOC
-
Tsukasa Baba,
Duke University
Ann and Sol Schreiber Mentored Investigator AwardUsing Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer
2003 Grant Recipients
-
Karen M. Vasquez, PhD,
MD Anderson Cancer Center
Individual Investigator AwardTrying to Understand the Mechanism for Cisplatin
-
Parameshwar Mahareshti, DVM,
University of Alabama - Birmingham
Individual Investigator AwardA New Combination Drug Treatment for Ovarian Cancer
-
Kuan-Chun Huang, PhD,
Brigham and Women’s Hospital
Ann and Sol Schreiber Mentored Investigator AwardA Possible New Marker for Drug Resistance of Ovarian Cancer
-
Thomas Franke, MD, PhD,
Columbia University Medical Center
Individual Investigator AwardFinding Molecules to Stop an Abnormal Signaling Pathway in Ovarian Cancer
2002 Grant Recipients
-
Fergus Couch, PhD,
Mayo Clinic
Individual Investigator AwardFinding Genes Associated with Drug Resistance in Ovarian Cancer
2001 Grant Recipients
-
Rebecca Liu, MD,
University of Michigan
Liz Tilberis Early Career AwardDysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Pathogenesis, Prognosis, and Chemoresistance
-
Steven W. Johnson, PhD,
University of Pennsylvania
Individual Investigator AwardCharacterizing Differential Gene Expression of Drug Sensitive and Resistant Ovarian Cancer